Jasmiel

Pregnancy Prevention

Jasmiel is primarily prescribed as a hormonal method of birth control to prevent pregnancy. It is most effective when taken consistently at the same time every day.

Premenstrual Dysphoric Disorder (PMDD)

This medication is used to treat the symptoms of PMDD in women who choose to use an oral contraceptive for birth control. PMDD is a condition that causes severe physical and emotional symptoms before a menstrual period begins. These symptoms may include:

• Persistent irritability, anxiety, or depression
• Difficulty concentrating
• Lack of energy or sleep disturbances
• Physical symptoms such as breast tenderness, headache, joint or muscle pain, and bloating

Acne Treatment

Jasmiel is also used to treat moderate acne vulgaris in females who are at least 14 years old, have started having menstrual periods, and desire an oral contraceptive for pregnancy prevention.

How Jasmiel Prevents Pregnancy

Jasmiel contains two active hormones: drospirenone (a progestin) and ethinyl estradiol (an estrogen). These hormones work together to prevent pregnancy through several different mechanisms.

The primary way Jasmiel works is by suppressing ovulation. This means the medication signals the body to stop the monthly release of an egg from the ovaries. Without the release of an egg, fertilization by sperm cannot occur.

In addition to stopping ovulation, Jasmiel causes other changes in the reproductive system to further reduce the chance of pregnancy:

• Thickening cervical mucus: The hormones cause the mucus in the cervix to become thicker and stickier. This change acts as a physical barrier that makes it difficult for sperm to travel into the uterus.
• Altering the uterine lining: Jasmiel changes the lining of the uterus (the endometrium). These changes make the environment less favorable for a fertilized egg to attach and grow.

Common Side Effects

Many people using Jasmiel experience mild side effects. These may include:

• Headache or migraine
• Nausea or vomiting
• Breast tenderness, pain, or enlargement
• Changes in menstrual periods, such as spotting or breakthrough bleeding
• Mood changes, including irritability or depression
• Weight gain
• Vaginal yeast infections

Serious Side Effects

While less common, Jasmiel can cause serious and potentially life-threatening side effects. Seek medical help immediately if you experience:

• Signs of a blood clot, such as sudden shortness of breath, chest pain, or pain and swelling in one leg
• Signs of a stroke or heart attack, including sudden numbness, weakness, severe headache, or vision changes
• High potassium levels, which may cause muscle weakness or an irregular heartbeat
• Liver problems, indicated by yellowing of the skin or eyes (jaundice) or dark urine
• Gallbladder disease
• New or worsening high blood pressure
• Severe allergic reactions, such as hives, swelling of the face or throat, and difficulty breathing

Boxed Warning: Smoking and Cardiovascular Risk

Cigarette smoking increases the risk of serious cardiovascular side effects from combined oral contraceptives. This risk increases with age, particularly in individuals over 35 years old, and with the number of cigarettes smoked. People who use Jasmiel are strongly advised not to smoke.

Thromboembolic Disorders

The use of Jasmiel increases the risk of serious blood clotting events, including:

• Venous thromboembolism (such as deep vein thrombosis or pulmonary embolism)
• Heart attack (myocardial infarction)
• Stroke

The risk of blood clots is highest during the first year of use or when restarting hormonal contraception after a break of four weeks or longer. Some studies suggest that products containing drospirenone may carry a higher risk of blood clots than those containing other types of progestins.

Hyperkalemia (High Potassium)

Jasmiel contains drospirenone, which can cause high potassium levels in the blood. This medication should not be used by individuals with conditions that predispose them to high potassium, such as renal impairment, hepatic impairment, or adrenal insufficiency. Monitoring of potassium levels may be necessary during the first month of treatment for those taking other medications that increase potassium, such as ACE inhibitors, ARBs, potassium-sparing diuretics, or daily long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Contraindications

Jasmiel should not be used by individuals with the following conditions:

• A high risk of arterial or venous thrombotic diseases (such as current or past blood clots)
• Current or history of breast cancer or other estrogen-sensitive cancers
• Liver tumors (benign or malignant) or active liver disease
• Renal impairment or adrenal insufficiency
• Undiagnosed abnormal uterine bleeding
• Pregnancy

Other Precautions

Liver Disease: Use should be discontinued if jaundice or significant liver enzyme elevations occur. Jasmiel is contraindicated in those with acute hepatitis or severe cirrhosis.

High Blood Pressure: Blood pressure should be monitored regularly, as hormonal contraceptives can cause an increase in blood pressure. If blood pressure rises significantly, the medication may need to be stopped.

Glucose and Lipid Metabolism: Individuals with prediabetes or diabetes should be monitored closely, as Jasmiel may affect glucose tolerance and insulin sensitivity.

Headache: A change in the pattern, frequency, or severity of migraines may require stopping the medication and evaluating the cause.

Gallbladder Disease: There is an increased risk of gallbladder disease in users of combined oral contraceptives.

Pregnancy

Jasmiel is used to prevent pregnancy and is not intended for use during pregnancy. If pregnancy is confirmed while taking this medication, it should be discontinued immediately. Research has generally shown that accidental use of oral contraceptives during early pregnancy does not increase the risk of birth defects or cause harm to the developing fetus.

Breastfeeding

The use of combined oral contraceptives like Jasmiel is typically not recommended for those who are breastfeeding until the infant has been completely weaned. Considerations include:

• Milk Production: Hormonal contraceptives containing estrogen may reduce the amount and quality of breast milk produced.
• Hormone Transfer: Small amounts of the hormones in Jasmiel can pass into breast milk. While adverse effects on nursing infants are not frequently reported, the long-term impact is not well-established.

Consult a healthcare professional to discuss the most appropriate birth control options while breastfeeding.

Dosage Forms

Jasmiel is available as a tablet for oral administration. The medication is supplied in a blister dispenser designed for a daily dosing schedule.

Tablet Types

The blister pack contains two different types of tablets to be taken in a specific order:

• Active tablets: These tablets contain the active hormonal medications.
• Inert tablets: These tablets do not contain active medication and serve as reminder pills to help maintain a daily routine.

FDA Approval and Indications

Jasmiel is approved by the U.S. Food and Drug Administration (FDA) for the following indications:

• Prevention of pregnancy.
• Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive for birth control.
• Treatment of moderate acne vulgaris in women at least 14 years of age who have reached menarche and desire oral contraception.

Boxed Warning

The FDA-approved labeling for Jasmiel includes a boxed warning concerning cigarette smoking and serious cardiovascular risks. Smoking increases the risk of major cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35, and with the number of cigarettes smoked. Consequently, Jasmiel is contraindicated for use in women who are over 35 years old and smoke.

Regulatory Status

Jasmiel is available only by prescription. It is a combination of drospirenone, a progestin, and ethinyl estradiol, an estrogen. The FDA has not established that Jasmiel is effective for the treatment of PMDD when used for more than three menstrual cycles, as its effectiveness for long-term use in PMDD has not been evaluated in clinical trials.

Weight Gain and Jasmiel

Weight gain is listed as one of the most common adverse reactions in clinical trials for Jasmiel. Because Jasmiel is a combination hormonal contraceptive, it can affect metabolism and fluid balance in some users.

Key points regarding weight changes include:

• Clinical Reports: In studies of drugs with the same active ingredients as Jasmiel, weight gain was frequently reported by users.
• Fluid Retention: Although the progestin in Jasmiel (drospirenone) has properties that may counteract fluid retention, some individuals may still experience changes in weight due to hormonal shifts.
• Individual Variation: Not everyone who takes Jasmiel will experience weight gain, and some may experience weight loss or no change at all.

If you are concerned about weight changes while taking Jasmiel, it is recommended to monitor your diet and activity levels and consult with a healthcare professional to determine if the medication is the cause.